Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- aldesleukin
- Oxilan (ioxilan)
Interactions between your drugs
aldesleukin ioxilan
Applies to: aldesleukin, Oxilan (ioxilan)
MONITOR: An increased incidence (12.6%) of acute, atypical reactions to iodinated contrast media has been observed in patients who have been previously treated with interleukin-2. The cause and mechanism have not been established. Symptoms generally have an onset of 1 to 4 hours and may include nausea, vomiting, diarrhea, fever, chills, flu-like symptoms, joint pain, rash, pruritus, hypotension, edema, and oliguria. Reactions have typically been reported when patients received iodinated contrast media within 4 weeks after the last dose of interleukin-2, but have also occurred several months after interleukin treatment.
MANAGEMENT: Patients should be monitored for adverse reactions after receiving iodinated contrast media, and symptomatic treatment initiated as clinically appropriate.
References (2)
- (2001) "Product Information. Proleukin (aldesleukin)." Chiron Therapeutics
- (2001) "Product Information. Ultravist (iopromide)." Berlex Laboratories
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to consumer interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Opdivo Qvantig
Opdivo Qvantig is used to treat adults with melanoma, non-small cell lung cancer, renal cell ...
Opdivo
Opdivo is used to treat many cancers, such as melanoma, non-small cell lung cancer, malignant ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Keytruda
Keytruda is used to treat multiple types of cancer such as melanoma, non-small cell lung cancer ...
Avastin
Avastin is used to brain tumors and cancers of the kidney, colon, rectum, or lung. Learn about side ...
Lenvima
Lenvima (lenvatinib) is used to treat thyroid cancer, advanced renal cell carcinoma, hepatocellular ...
Cabometyx
Cabometyx is used to treat advanced kidney cancer, liver cancer, thyroid cancer, and pancreatic and ...
Tecentriq
Tecentriq (atezolizumab) is a monoclonal antibody used to treat non-small cell lung cancer, small ...
Yervoy
Yervoy (ipilimumab) is a cancer treatment used for lung cancer, melanoma, renal cell carcinoma ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.